immunity News and Research

RSS

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and cause disease and death in many countries even today. At present, there is no effective treatment. A recent study published on the preprint server bioRxiv in August 2020 reports the potential of a new class of drugs called CAR NK cells, which could be used off-the-shelf to treat this disease.

17 Aug 2020

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

Frequently used serology test may not detect SARS-CoV-2 antibodies, shows study

Two different types of detectable antibody responses in SARS-CoV-2 (COVID-19) tell very different stories and may indicate ways to enhance public health efforts against the disease, according to researchers at The University of Texas MD Anderson Cancer Center.

15 Aug 2020

Pregnant mother's immune conditions linked to behavioral, emotional problems in children with autism

Children with autism born to mothers who had immune conditions during their pregnancy are more likely to have behavioral and emotional problems, a UC Davis Health study has found.

15 Aug 2020

Influenza-virus-based vaccine platform another viable option against SARS-CoV-2

In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).

14 Aug 2020

Can SARS-CoV-2 die out without immunity?

As the COVID-19 pandemic continues to take thousands of lives every day in different parts of the world, vaccine and antiviral research is continuing, as the only hope of emergence from under its shadow. However, a recent study by researcher Bhavin S Khatri at Imperial College London and published on the preprint server medRxiv* in August 2020 suggests that the pandemic may die out more rapidly than thought, provided the reproduction number is kept low.

14 Aug 2020

Preliminary Mayo Clinic results from convalescent plasma in 35,322 patients

A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.

14 Aug 2020

Experimental COVID-19 vaccine prevents severe disease in mice

Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.

14 Aug 2020

Natural controllers shed light on immunity mechanisms against hepatitis B

Infections in humans caused by the hepatitis B virus (HBV) represent a major public health problem. Despite the availability of effective protective vaccines, more than 250 million individuals worldwide are chronically infected according to WHO estimates.

13 Aug 2020

Researchers discover how gut bacteria help the immune system to battle cancerous tumors

Researchers with the Snyder Institute for Chronic Diseases at the Cumming School of Medicine have discovered which gut bacteria help our immune system battle cancerous tumors and how they do it.

13 Aug 2020

Researchers outline how Zika virus suppresses the host immune system

A research team led by scientists at the University of California, Riverside, has outlined how the Zika virus, which constituted an epidemic threat in 2016, suppresses the immune system of its host.

12 Aug 2020

Researchers recommend inclusion of pregnant and breastfeeding women in COVID-19 vaccine trials

Researchers from the United Kingdom have published their views on the inclusion of pregnant women in clinical trials for vaccines against the novel coronavirus and the related challenges this presents. Their article titled, “Inclusion of pregnant women in COVID-19 vaccine development”, was published yesterday in The Lancet Infectious Diseases.

12 Aug 2020

Experimental vaccine effective at preventing pneumonia in COVID-19-infected mice

An experimental vaccine is effective at preventing pneumonia in mice infected with the COVID-19 virus, according to a study from Washington University School of Medicine in St. Louis.

12 Aug 2020

Focusing on human enzymes and not SARS-CoV-2 could help treat COVID-19

Now, breakthrough research into malaria suggests targeting enzymes from the human host, rather than from the pathogen itself. The new research could pave the way for effective treatments for a wide range of infectious diseases, including the coronavirus disease (COVID-19).

11 Aug 2020

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

11 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

COVID-19 patient with repeatedly undetectable SARS-CoV-2 antibodies

A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.

10 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Method provides new insight into brain cells that maintain body's master circadian clock.

UT Southwestern scientists have developed a genetically engineered mouse and imaging system that lets them visualize fluctuations in the circadian clocks of cell types in mice.

7 Aug 2020